ANDA 78418, held by Strides Pharma. Topiramate.
As of Nov 15, 2026, ANDA 78418 (Topiramate), held by Strides Pharma, was first approved by FDA on Oct 14, 2009, with 8 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Oct 14, 2009 | Original application | Approved | None posted |
| Topiramate15MG · capsule;oral | Topiramate | Rx |
| Topiramate25MG · capsule;oral | Topiramate | Rx |
| Topiramate50MG · capsule;oral | Topiramate | Rx |
| Aug 21, 2025 | Supplement 4Labeling · Standard review | Approved | None posted |
| Aug 21, 2025 | Supplement 6Labeling · Standard review | Approved | None posted |
| Aug 21, 2025 | Supplement 8Labeling · Standard review | Approved | None posted |
| Aug 21, 2025 | Supplement 9Labeling · Standard review | Approved | None posted |
| Aug 21, 2025 | Supplement 11Labeling · Standard review | Approved | None posted |
| Aug 21, 2025 | Supplement 13Labeling · Standard review | Approved | None posted |
| Jan 6, 2017 | Supplement 3Labeling · Standard review | Approved | None posted |
| Dec 23, 2010 | Supplement 1Labeling | Approved | None posted |
| Oct 14, 2009 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters